{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Lie IA"],"funding":["Neuro-SysMed at Haukeland University Hospital","Pronova Biocare","Amersham Health","University of Bergen","Dutch MS Research Foundation","Merck Serono, Norway","Helse Vest","Research Council of Norway","National Institute for Health Research (NIHR) biomedical research centre at University College London Hospitals NHS Foundation Trust","Norwegian Multiple Sclerosis Society","Novartis"],"pubmed_abstract":["<h4>Background</h4>The predictive value of serum neurofilament light chain (sNfL) on long-term prognosis in multiple sclerosis (MS) is still unclear.<h4>Objective</h4>Investigate the relation between sNfL levels over a 2-year period in patients with relapsing-remitting MS, and clinical disability and grey matter (GM) atrophy after 10 years.<h4>Methods</h4>85 patients, originally enrolled in a multicentre, randomised trial of ω-3 fatty acids, participated in a 10-year follow-up visit. sNfL levels were measured by Simoa quarterly until month 12, and then at month 24. The appearance of new gadolinium-enhancing (Gd+) lesions was assessed monthly between baseline and month 9, and then at months 12 and 24. At the 10-year follow-up visit, brain atrophy measures were obtained using FreeSurfer.<h4>Results</h4>Higher mean sNfL levels during early periods of active inflammation (Gd+ lesions present or recently present) predicted lower total (β=-0.399, p=0.040) and deep (β=-0.556, p=0.010) GM volume, lower mean cortical thickness (β=-0.581, p=0.010) and higher T2 lesion count (β=0.498, p=0.018). Of the clinical outcomes, higher inflammatory sNfL levels were associated with higher disability measured by the dominant hand Nine-Hole Peg Test (β=0.593, p=0.004). Mean sNfL levels during periods of remission (no Gd+ lesions present or recently present) did not predict GM atrophy or disability progression.<h4>Conclusion</h4>Higher sNfL levels during periods of active inflammation predicted more GM atrophy and specific aspects of clinical disability 10 years later. The findings suggest that subsequent long-term GM atrophy is mainly due to neuroaxonal degradation within new lesions."],"journal":["Journal of neurology, neurosurgery, and psychiatry"],"pagination":["jnnp-2021-328568"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9304101"],"repository":["biostudies-literature"],"pubmed_title":["Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study."],"pmcid":["PMC9304101"],"funding_grant_id":["MS 18-358f","912020","288164"],"pubmed_authors":["Holmoy T","Myhr KM","Bo L","Midgard R","Harbo HF","Kacar S","Barkhof F","Gosal S","Kvistad SS","Wergeland S","Vedeler CA","Bru A","Wesnes K","Kleveland G","Lie IA","Brouwer I","Vrenken H","Oksendal N","Torkildsen O","Edland A","Sorenes YS","Eikeland R","Teunissen CE","Varhaug KN"],"additional_accession":[]},"is_claimable":false,"name":"Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study.","description":"<h4>Background</h4>The predictive value of serum neurofilament light chain (sNfL) on long-term prognosis in multiple sclerosis (MS) is still unclear.<h4>Objective</h4>Investigate the relation between sNfL levels over a 2-year period in patients with relapsing-remitting MS, and clinical disability and grey matter (GM) atrophy after 10 years.<h4>Methods</h4>85 patients, originally enrolled in a multicentre, randomised trial of ω-3 fatty acids, participated in a 10-year follow-up visit. sNfL levels were measured by Simoa quarterly until month 12, and then at month 24. The appearance of new gadolinium-enhancing (Gd+) lesions was assessed monthly between baseline and month 9, and then at months 12 and 24. At the 10-year follow-up visit, brain atrophy measures were obtained using FreeSurfer.<h4>Results</h4>Higher mean sNfL levels during early periods of active inflammation (Gd+ lesions present or recently present) predicted lower total (β=-0.399, p=0.040) and deep (β=-0.556, p=0.010) GM volume, lower mean cortical thickness (β=-0.581, p=0.010) and higher T2 lesion count (β=0.498, p=0.018). Of the clinical outcomes, higher inflammatory sNfL levels were associated with higher disability measured by the dominant hand Nine-Hole Peg Test (β=0.593, p=0.004). Mean sNfL levels during periods of remission (no Gd+ lesions present or recently present) did not predict GM atrophy or disability progression.<h4>Conclusion</h4>Higher sNfL levels during periods of active inflammation predicted more GM atrophy and specific aspects of clinical disability 10 years later. The findings suggest that subsequent long-term GM atrophy is mainly due to neuroaxonal degradation within new lesions.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-06-21T03:19:37.899Z","creation":"2026-06-21T03:12:35.323Z"},"accession":"S-EPMC9304101","cross_references":{"pubmed":["35649699"],"doi":["10.1136/jnnp-2021-328568"]}}